title: [Molecular target therapy for colonic neoplasms].
authors: Eiji
authors: E
authors: Oki
authors: Mitsuhiko
authors: M
authors: Ota
authors: Takuya
authors: T
authors: Honbo
authors: Akinori
authors: A
authors: Egashira
authors: Eriko
authors: E
authors: Tokunaga
authors: Noriaki
authors: N
authors: Sadanaga
authors: Masaru
authors: M
authors: Morita
authors: Yoshihiro
authors: Y
authors: Kakeji
authors: Yoshihiko
authors: Y
authors: Maehara
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab; D000068818:Cetuximab; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000209:etiology*; D015195:Drug Design; D004359:Drug Therapy, Combination; D066246:ErbB Receptors / Q000276:immunology; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D066246:ErbB Receptors; D000068818:Cetuximab